Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today the top-line results from the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.
Find an actor

MedTech Investing Europe 2018 (MTi)24.04.2018

The 26th MedTech Investing Europe Conference will be held on 24 and 25 April 2018 at the Royal Savoy Hotel in...

Anergis and Mymetics Start Research Collaboration Project

Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines,...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn